The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.

Inclusion Criteria

1. Age ≥ 18 years on the date of consent
2. Ability for participant to comply with study requirements
3. Written informed consent

Exclusion Criteria

1. Pregnant or breastfeeding
2. Having an active atrial fibrillation episode as seen on most current 12-lead ECG
3. Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillator).
4. External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan
5. Inability to lie down in a supine/inclined position and stay still on the examination bed
6. Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol

Study candidates may be identified and recruited in one of the following ways:

• Amyloid Clinic (or other cardiology specialty clinics)
• In-patient service at the study institution.
• From the Principal Investigator or Co-Investigator clinical practices
• Referral from other hospitals